Bound to Happen: Inherent Property Leaves No Question of Reasonable Expectation of Success
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Sashank Krothapally and Nathan D. Reeves
CYTIVA BIOPROCESS R&D AB V. JSR CORP.
Before Prost, Taranto, and Hughes. Appeal from the Patent Trial and Appeal Board.
Summary: A claim limitation merely reciting an inherent property or result of an otherwise obvious composition or process can be found obvious without finding a reasonable expectation of success.
JSR filed six inter partes reviews on three patents owned by Cytiva. The patents related to compositions for chromatography matrices and processes for isolating target compounds using those matrices. The Board held that all of the composition claims and most of the process claims were unpatentable, but found four dependent process claims not unpatentable. The Board held that JSR’s obviousness arguments regarding the dependent process claims required a showing of reasonable expectation of success. Cytiva appealed on the claims found unpatentable, and JSR cross-appealed on the four dependent claims found not unpatentable.
The Federal Circuit affirmed the Board’s decision that most of the challenged claims were unpatentable, and reversed the Board’s decision that the four dependent process claims were not unpatentable. The Court noted that the dependent process claims had no material differences from corresponding composition claims that the Board found unpatentable for merely reciting an inherent feature. The Federal Circuit disagreed with the Board’s requirement that JSR show a reasonable expectation of success for the dependent process claims, since if a limitation of claim is inherent “there is no question of a reasonable expectation of success in achieving it.” Thus, because the dependent process claims merely recited the result of an inherent property of an otherwise obvious composition, the claims were obvious.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…